Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARWR Arrowhead Research Corporation

盘前交易 09-10 08:29:58 EDT

82.63

-2.48

-2.91%

盘前82.49

-0.14-0.17%

08:16 EDT

最高87.20	最低82.16	成交量366.84万
今开84.65	昨收85.11	日振幅5.92%
总市值116.39亿	流通市值100.81亿	总股本1.41亿
成交额3.05亿	换手率3.01%	流通股本1.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARWR","market":"US","secType":"STK","nameCN":"Arrowhead Research Corporation","latestPrice":82.63,"timestamp":1788984000000,"preClose":85.11,"halted":0,"volume":3668389,"hourTrading":{"tag":"盘前","latestPrice":82.4936,"preClose":82.63,"latestTime":"08:16 EDT","volume":335,"amount":27603.059989999998,"timestamp":1789042581140,"change":-0.1364,"changeRate":-0.001651,"amplitude":0.018879},"delay":0,"changeRate":-0.029138761602631937,"floatShares":122000000,"shares":140857021,"eps":-2.28382,"marketStatus":"盘前交易","change":-2.48,"latestTime":"09-10 08:29:58 EDT","open":84.65,"high":87.2,"low":82.16,"amount":304540116.9686,"amplitude":0.059217,"askPrice":82.4,"askSize":10,"bidPrice":80,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-2.28382,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":740203200000,"exchange":"NASDAQ","adjPreClose":82.63,"preHourTrading":{"tag":"盘前","latestPrice":82.4936,"preClose":82.63,"latestTime":"08:16 EDT","volume":335,"amount":27603.059989999998,"timestamp":1789042581140,"change":-0.1364,"changeRate":-0.001651,"amplitude":0.018879},"postHourTrading":{"tag":"盘后","latestPrice":81.0794,"preClose":82.63,"latestTime":"19:50 EDT","volume":1730585,"amount":143002551.8408,"timestamp":1788997825163,"change":-1.5506,"changeRate":-0.018766,"amplitude":0.041147},"volumeRatio":2.7991085005008274,"impliedVol":0.5544,"impliedVolPercentile":0.224},"requestUrl":"/m/hq/s/ARWR","defaultTab":"news","newsList":[{"id":"1117094130","title":"Arrowhead Pharmaceuticals：Plozasiran在III期研究中展现良好安全性与耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1117094130","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117094130?lang=zh_cn&edition=full","pubTime":"2026-08-30 23:33","pubTimestamp":1788103990,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals近日宣布，其研发的Plozasiran在III期临床研究中表现出令人满意的安全性和耐受性特征。这一积极的结果无疑为该公司在代谢疾病领域的布局注入了强心剂。值得关注的是，这项III期研究的数据进一步验证了Plozasiran作为潜在治疗方案的可行性。Plozasiran所呈现的有利安全谱，或将为特定疾病群体带来新的希望。随着研究数据的持续积累与解读，Plozasiran的临床应用前景正逐渐变得清晰。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116619525","title":"Arrowhead Pharmaceuticals拟于2026年底前凭优先审评券向美国FDA提交补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1116619525","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116619525?lang=zh_cn&edition=full","pubTime":"2026-08-30 23:32","pubTimestamp":1788103929,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals（股票代码：ARWR）宣布，计划于2026年底之前，借助优先审评券，向美国食品药品监督管理局（FDA）提交补充新药申请（sNDA）。这一举措标志着公司在推进其候选药物监管审批进程中迈出关键一步。优先审评券的运用，有望显著缩短FDA对新药申请的审评周期，从而加速产品走向市场的步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107393929","title":"箭头制药（Arrowhead Pharmaceuticals）公布三期Shasta-3和Shasta-4数据：Plozasiran显著减少重度高甘油三酯血症患者的急性胰腺炎事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1107393929","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107393929?lang=zh_cn&edition=full","pubTime":"2026-08-30 23:31","pubTimestamp":1788103875,"startTime":"0","endTime":"0","summary":"两项研究均采用随机、双盲、安慰剂对照设计，旨在评估Plozasiran对极高甘油三酯水平患者的治疗潜力。结果显示，与安慰剂组相比，接受Plozasiran治疗的患者群体中，急性胰腺炎事件的发生率呈现具有统计学意义的下降。这些结果表明，Plozasiran在重度高甘油三酯血症人群中具有可接受的风险-获益比。总而言之，Shasta-3和Shasta-4的积极结果，为Plozasiran的临床开发注入了强心剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178953219","title":"德国家族性乳糜微粒血症综合征（FCS）患者迎来新疗法：Redemplo®（Plozasiran）可有效降低甘油三酯","url":"https://stock-news.laohu8.com/highlight/detail?id=1178953219","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178953219?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:34","pubTimestamp":1786973661,"startTime":"0","endTime":"0","summary":"在德国，患有家族性乳糜微粒血症综合征的患者如今迎来了一项令人振奋的治疗新选择——Redemplo。这一创新药物旨在显著降低患者体内异常升高的甘油三酯水平，为这一罕见且棘手的代谢性疾病患者群体带来了新的曙光。Redemplo作为一种靶向RNA干扰疗法，通过精准抑制肝脏中APOC3基因的表达，从而有效调节脂质代谢，降低血浆甘油三酯浓度。随着Redemplo在德国正式可供使用，相关医疗体系也正积极整合这一新选项，力求在最短时间内将其纳入规范治疗流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154955623","title":"Arrowhead制药计划在2026年底前使用优先审评券，为Plozasiran提交重度高甘油三酯血症补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1154955623","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154955623?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:01","pubTimestamp":1785873671,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals（股票代码：ARWR）宣布，该公司计划在2026年年底之前，利用一张优先审评券（Priority Review Voucher），为旗下药物Plozasiran提交针对重度高甘油三酯血症（Severe Hypertriglyceridemia）的补充新药申请（sNDA）。这一举动显示出该公司正加速推进其关键管线的监管审批进程。通过使用这一宝贵资源，Arrowhead希望缩短审评周期，使治疗方案更快惠及患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","ARWR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147562503","title":"Arrowhead制药完成全球3期Yosemite研究入组，探索Zodasiran治疗纯合子家族性高胆固醇血症","url":"https://stock-news.laohu8.com/highlight/detail?id=1147562503","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147562503?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:31","pubTimestamp":1785151872,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals（股票代码：ARWR，中文名：Arrowhead Research Corporation）宣布，其针对Zodasiran治疗纯合子家族性高胆固醇血症的全球3期Yosemite研究已全面完成患者入组。这一里程碑标志着该候选药物在临床开发上迈出了关键一步，旨在为这一罕见且严重的遗传性脂质代谢疾病提供新的治疗选项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125758170","title":"异动解读｜Arrowhead Research Corporation盘中上涨19.25%，核心管线Plozasiran后期试验数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1125758170","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125758170?lang=zh_cn&edition=full","pubTime":"2026-07-22 21:39","pubTimestamp":1784727594,"startTime":"0","endTime":"0","summary":"7月22日，Arrowhead Research Corporation盘中上涨19.25%，报89.54美元/股，成交额1.14亿美元。消息面上，公司公布核心药物Plozasiran在两项关键后期临床试验Shasta-3和Shasta-4中成功达到主要终点，分别实现79%和81%的中位甘油三酯降低率；在高危患者群体中实现急性胰腺炎事件100%的风险削减，且安全性特征稳定，未出现新安全信号。Plozasiran此前已以商品名Redemplo获得欧盟上市许可，用于治疗家族性乳糜微粒血症综合征。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141151307","title":"Arrowhead Pharmaceuticals股价盘前飙升18.1%，血脂药物达后期试验目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1141151307","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141151307?lang=zh_cn&edition=full","pubTime":"2026-07-22 20:52","pubTimestamp":1784724738,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals的股价在盘前交易时段大幅上涨18.1%，此前该公司宣布其研发的一款血脂药物在后期临床试验中成功达到了主要目标。\n这一积极进展显著提振了投资者信心，推动该公司股票在开盘前即录得强劲涨幅。该药物的成功标志着Arrowhead在心血管疾病治疗领域的研发取得了关键性突破。\n市场分析人士指出，后期试验目标的达成通常意味着药物距离最终获批上市更近一步，这为公司未来的商业化前景带来了明确利好。此次股价的剧烈反应，也反映了市场对该创新疗法潜在价值的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARWR","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119942739","title":"异动解读｜Arrowhead Pharmaceuticals盘前上涨8.64%，核心管线Plozasiran多项关键试验数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1119942739","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119942739?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:36","pubTimestamp":1784720197,"startTime":"0","endTime":"0","summary":"7月22日，Arrowhead Pharmaceuticals盘前上涨8.64%，报84.0美元/股，成交额6.85万美元。消息面上，公司公布旗下药物Plozasiran在两项关键临床试验Shasta-3和Shasta-4中分别实现79%和81%的中位甘油三酯降低率；同时该药物在高危患者群体中实现急性胰腺炎事件100%的风险削减，且未出现新的安全信号，安全性特征稳定。Plozasiran此前已以商品名Redemplo获得欧盟上市许可，用于治疗家族性乳糜微粒血症综合征。此次多项积极数据同步发布，进一步拓宽了该药物在心血管代谢疾病领域的适应症前景。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128819834","title":"Arrowhead Pharmaceuticals旗下Plozasiran展现一致安全性，未出现新安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1128819834","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128819834?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:33","pubTimestamp":1784719981,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布，其研发中的药物Plozasiran在临床试验中持续展现出稳定的安全性特征，期间未观察到新的安全信号。这一结果进一步支持了该药物的开发前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128516817","title":"Arrowhead Pharmaceuticals旗下Plozasiran在Shasta-3和Shasta-4试验中实现中位甘油三酯降低79%和81%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128516817","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128516817?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:31","pubTimestamp":1784719877,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals公司宣布，其研究性药物Plozasiran在两项关键临床试验——Shasta-3与Shasta-4中，取得了显著成果。数据显示，该药物分别实现了79%和81%的中位甘油三酯降低率，展现出强大的治疗潜力。\n这一积极结果标志着公司在心血管代谢疾病治疗领域的重要进展，也为Plozasiran的后续开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173896289","title":"Arrowhead Pharmaceuticals 候选药物 Plozasiran 显著降低急性胰腺炎事件，高危患者群体实现100%风险削减","url":"https://stock-news.laohu8.com/highlight/detail?id=1173896289","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173896289?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:31","pubTimestamp":1784719873,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals 宣布，其研发中的候选药物 Plozasiran 在临床试验中展现出令人瞩目的效果，能够显著降低急性胰腺炎事件的发生率。尤为引人注目的是，在那些被定义为高风险的患者群体中，该药物实现了急性胰腺炎事件100%的削减，这一数据凸显了其潜在的突破性治疗价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104621273","title":"异动解读｜Arrowhead Research Corporation盘中下跌7.92%，报77.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104621273","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104621273?lang=zh_cn&edition=full","pubTime":"2026-07-11 00:13","pubTimestamp":1783700022,"startTime":"0","endTime":"0","summary":"7月11日，Arrowhead Research Corporation盘中下跌7.92%，报77.35美元/股，成交额9839.65万美元。Arrowhead Research Corporation所在的生物科技行业中，整体表现疲弱，个股中，艾伯维公司跌1.33%，Ionis Pharmaceuticals跌8.74%，Moderna跌10.51%，吉利德科学跌3.24%，阿尔尼拉姆制药公司跌4.30%。Arrowhead Pharmaceuticals, Inc.最初于1989年在南达科他州注册成立，后在特拉华州重新注册成立。该公司开发药物，通过沉默疾病的基因来治疗疑难杂症。目前有18个Arrowhead发现的候选药物处于早期（1期）至晚期（3期）的临床试验阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141922913","title":"Arrowhead Pharmaceuticals获欧盟批准Redemplo® (Plozasiran)用于降低家族性乳糜微粒血症综合征成人患者甘油三酯","url":"https://stock-news.laohu8.com/highlight/detail?id=1141922913","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141922913?lang=zh_cn&edition=full","pubTime":"2026-06-23 00:34","pubTimestamp":1782146067,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布，其药物Redemplo® (Plozasiran)已获得欧盟委员会授予的上市许可，用于降低患有家族性乳糜微粒血症综合征（FCS）的成人患者的甘油三酯水平。FCS是一种罕见且严重的遗传性疾病，其特征是血液中甘油三酯水平极度升高，可导致危及生命的胰腺炎。该授权标志着Arrowhead Pharmaceuticals在罕见病治疗领域取得的重要进展，为欧洲的FCS患者提供了一种新的治疗选择。公司表示，将致力于尽快将这一创新疗法带给有需要的患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ARWR","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166564197","title":"异动解读｜Arrowhead制药盘中上涨5.06%，阿尔茨海默病siRNA药物临床进展持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1166564197","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166564197?lang=zh_cn&edition=full","pubTime":"2026-06-18 00:13","pubTimestamp":1781712837,"startTime":"0","endTime":"0","summary":"6月17日，Arrowhead制药盘中上涨5.06%，报80.25美元/股，成交额5127.81万美元。消息面上，公司近期持续受到ARO-MAPT临床进展催化。该药物基于TRiM BBB平台开发，利用siRNA偶联转铁蛋白受体靶向配体，通过皮下注射给药跨越血脑屏障，在全脑范围内沉默MAPT基因，用于治疗阿尔茨海默病等Tau蛋白病。临床前数据显示，ARO-MAPT在非人灵长类动物中实现高达70-80%的mRNA敲降，覆盖神经元、星形胶质细胞等多种细胞类型。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145907277","title":"异动解读｜Arrowhead制药盘中上涨5.89%，阿尔茨海默病siRNA药物初步临床数据披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1145907277","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145907277?lang=zh_cn&edition=full","pubTime":"2026-06-12 01:47","pubTimestamp":1781200051,"startTime":"0","endTime":"0","summary":"6月11日，Arrowhead制药盘中上涨5.89%，报75.0美元/股，成交额4540.69万美元。消息面上，公司披露了基于TRiM BBB平台开发的siRNA药物ARO-MAPT7的初步临床结果。该药物利用siRNA偶联转铁蛋白受体靶向配体，通过皮下注射给药，旨在高效跨越血脑屏障，在全脑范围内沉默MAPT基因，用于治疗阿尔茨海默病等Tau蛋白病。这一数据的公布标志着公司在中枢神经系统RNA干扰疗法领域取得关键进展，市场对其BBB递送技术平台的潜力给予积极反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103261526","title":"Arrowhead Pharmaceuticals 在第九十四届欧洲动脉粥样硬化协会大会上公布新的积极临床心脏代谢数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1103261526","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103261526?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:00","pubTimestamp":1779804017,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals 在第九十四届欧洲动脉粥样硬化协会（EAS）大会上，公布了其最新的积极临床心脏代谢数据。这些新发现为该公司的相关研究项目提供了进一步的支持，并展示了其在心脏代谢疾病治疗领域的潜力。数据的呈现增强了投资者和行业观察人士对公司研发管线进展的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161698398","title":"Madrigal与Arrowhead达成合作：预付2500万美元，里程碑付款最高达9.75亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161698398","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161698398?lang=zh_cn&edition=full","pubTime":"2026-05-05 20:11","pubTimestamp":1777983115,"startTime":"0","endTime":"0","summary":"生物技术公司Arrowhead Pharmaceuticals宣布与Madrigal Pharmaceuticals达成一项重要合作协议。根据协议条款，Madrigal将向Arrowhead支付2500万美元的预付款，未来还可能基于研发里程碑支付最高9.75亿美元的额外款项。\n这项合作涉及Arrowhead在非酒精性脂肪性肝炎（NASH）治疗领域的专有技术。双方将共同推进相关疗法的开发，Arrowhead有望通过达成特定开发、注册和商业里程碑获得总额高达10亿美元的收益。此次合作彰显了Arrowhead在RNA干扰疗法领域的技术实力获得业界认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138499617","title":"Arrowhead制药三期研究显示Redemplo使甘油三酯较基线中位数降低80%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138499617","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138499617?lang=zh_cn&edition=full","pubTime":"2026-05-01 19:31","pubTimestamp":1777635096,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布其候选药物Redemplo在三期临床试验中取得突破性成果。数据显示，该药物能够将患者甘油三酯水平从基线值中位数降低80%，展现出卓越的降脂疗效。\n这一里程碑式的研究结果进一步验证了Redemplo在治疗高甘油三酯血症方面的潜力。显著的疗效指标为该药物未来获批上市奠定了坚实基础，同时为相关患者群体提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134103027","title":"财报前瞻｜Arrowhead Research Corporation本季度营收预计增153.09%，机构多数看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1134103027","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134103027?lang=zh_cn&edition=full","pubTime":"2026-04-30 15:22","pubTimestamp":1777533756,"startTime":"0","endTime":"0","summary":"Arrowhead Research Corporation将于2026年05月07日（盘后）披露财报，市场关注营收波动、利润弹性与合作里程碑兑现节奏。市场一致预期显示，本季度公司营收预计为7,569.00万美元，同比增长153.09%；调整后每股收益预计为-1.19美元，同比下降499.63%；息税前利润预计为-1.77亿美元，同比下降356.25%。发展前景中，Sarepta合作被视为最具驱动力的现有业务，当前其6.97亿美元的体量与高占比，叠加市场对本季度营收同比增长153.09%的预期，共同构成短期业绩的主要支撑与不确定来源。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Arrowhead Research Corporation本季度营收预计增153.09%，机构多数看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arrowheadpharma.com","stockEarnings":[{"period":"1week","weight":-0.0321},{"period":"1month","weight":-0.0645},{"period":"3month","weight":0.1105},{"period":"6month","weight":0.501},{"period":"1year","weight":1.9798},{"period":"ytd","weight":0.2446}],"compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0138},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1512},{"period":"1year","weight":0.1723},{"period":"ytd","weight":0.118}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arrowhead Pharmaceuticals, Inc.最初于1989年在南达科他州注册成立，后在特拉华州重新注册成立。该公司开发药物，通过沉默疾病的基因来治疗疑难杂症。使用广泛的RNA化学组合和高效的递送模式，该公司的疗法触发RNA干扰机制，以诱导目标基因的快速、深度和持久敲低。目前有18个Arrowhead发现的候选药物处于早期（1期）至晚期（3期）的临床试验阶段。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.009831},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.008632},{"month":3,"riseRate":0.5,"avgChangeRate":0.050374},{"month":4,"riseRate":0.5,"avgChangeRate":0.032513},{"month":5,"riseRate":0.409091,"avgChangeRate":0.01068},{"month":6,"riseRate":0.590909,"avgChangeRate":0.024487},{"month":7,"riseRate":0.590909,"avgChangeRate":0.0537},{"month":8,"riseRate":0.409091,"avgChangeRate":0.011388},{"month":9,"riseRate":0.545455,"avgChangeRate":0.061349},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.028468},{"month":11,"riseRate":0.545455,"avgChangeRate":0.060925},{"month":12,"riseRate":0.454545,"avgChangeRate":0.054899}],"exchange":"NASDAQ","name":"Arrowhead Research Corporation","nameEN":"Arrowhead Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Arrowhead Research Corporation(ARWR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Arrowhead Research Corporation,ARWR,Arrowhead Research Corporation股票,Arrowhead Research Corporation股票老虎,Arrowhead Research Corporation股票老虎国际,Arrowhead Research Corporation行情,Arrowhead Research Corporation股票行情,Arrowhead Research Corporation股价,Arrowhead Research Corporation股市,Arrowhead Research Corporation股票价格,Arrowhead Research Corporation股票交易,Arrowhead Research Corporation股票购买,Arrowhead Research Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Arrowhead Research Corporation(ARWR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}